How will you use xanomeline-trospium (KarXT, Cobenfy) for patients with schizophrenia?  

KarXT, an investigational drug for schizophrenia developed by Karuna Therapeutics, combines xanomeline and trospium and is currently under FDA review. Unlike traditional antipsychotics that work by blocking post-synaptic dopamine receptors, xanomeline functions as an agonist at M1 and M4 receptors. ...

I appreciate Dr. @Lim's response that summarizes some of the study data, but want to add a few details from my review of the available literature. I also am glad to hear about a new mechanism, even if the ultimate efficacy is thought to be due to downstream D2 blockade. However, I do not currently ...

I've started it in a few patients with good results regarding psychosis. It's the side effects that need to be monitored as well as the patient being knowledgeable on when to take it (one hour before a meal or two hours after a meal). They are starting a study about taking it on an empty stomach or ...

Until now, we were focusing to block D1, D5, and D2, D3, D4. Now new theory of agonist effect to M1 and M4. I need more informartions and strong evidances to support my ethical practice to tell my patients what is good for them!